Monopar Therapeutics — Director's Dealing 2024

Jun 21, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2024-06-18

Reporting Person: Cittadine Andrew (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-06-18	Common Stock	P	12000	$0.86	Acquired	165624	Direct
2024-06-20	Common Stock	P	20508	$0.7438	Acquired	186132	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.73691 to $0.75860, inclusive. The reporting person undertakes to provide to Monopar Therapeutics, any security holder of Monopar Therapeutics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the preceding sentence.